Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up
(2008) In International Journal of Gynecological Cancer 18(4). p.803-808- Abstract
- There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin... (More)
- There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1254937
- author
- Sorbe, B. ; Andersson, H. ; Boman, K. ; Rosenberg, P. and Kalling, Mårten LU
- organization
- publishing date
- 2008
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- chemotherapy, carboplatin, paclitaxel, endometrial cancer
- in
- International Journal of Gynecological Cancer
- volume
- 18
- issue
- 4
- pages
- 803 - 808
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000257662900030
- scopus:47649086616
- pmid:17944917
- ISSN
- 1048-891X
- DOI
- 10.1111/j.1525-1438.2007.01094.x
- language
- English
- LU publication?
- yes
- id
- 258f82f9-f9df-43c4-9dfb-9a04419d274f (old id 1254937)
- date added to LUP
- 2016-04-01 11:39:33
- date last changed
- 2022-07-29 08:09:11
@article{258f82f9-f9df-43c4-9dfb-9a04419d274f,
abstract = {{There is no generally accepted standard chemotherapy in treatment of advanced and recurrent endometrial carcinoma. Cisplatin and doxorubicin with or without cyclophosphamide are widely used. Response rates have improved with combination chemotherapy compared with single-agent therapy. A platinum analog seems to be an important part of the chemotherapy regimen. Since few patients are cured from their disease and since the duration of response is short, further improvement of this therapy is warranted. During the past years, the taxanes (paclitaxel) are being added to prior evaluated regimens and not only improved response rates are reported but also increased toxicity is observed. In a prospective, phase II, multicenter study, carboplatin (area under the curve = 5) and paclitaxel (175 mg/m(2)) were evaluated in treatment of primary advanced and recurrent endometrial carcinoma. In total, 66 patients were recruited during the years 2000-2004. Eighteen primary advanced tumors and 48 recurrences were treated. All histologic types and tumor grades were allowed. The median follow-up was 57 months (range 37-69 months). The overall response rate was 67% (95% CI 55-78). The complete response rate was 29% and the partial response rate 38%. Primary advanced and recurrent tumors as well as endometrioid and nonendometrioid tumors showed similar response rates. The median response duration was 14 months. The 1- and 3-year survival rates were 82% and 33%, respectively. The main toxicities were hematologic and neurologic (sensory neuropathy). The response rates were encouraging, superior to prior platinum-containing regimens, but response duration and the long-term survival rate were still short. The neurologic toxicity was frequent and was a substantial problem in this series of patients. Further research is highly needed to improve the treatment of advanced and recurrent endometrial cancer.}},
author = {{Sorbe, B. and Andersson, H. and Boman, K. and Rosenberg, P. and Kalling, Mårten}},
issn = {{1048-891X}},
keywords = {{chemotherapy; carboplatin; paclitaxel; endometrial cancer}},
language = {{eng}},
number = {{4}},
pages = {{803--808}},
publisher = {{BMJ Publishing Group}},
series = {{International Journal of Gynecological Cancer}},
title = {{Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel - long-term follow-up}},
url = {{http://dx.doi.org/10.1111/j.1525-1438.2007.01094.x}},
doi = {{10.1111/j.1525-1438.2007.01094.x}},
volume = {{18}},
year = {{2008}},
}